Stocks · Healthcare · Biotechnology
Coya Therapeutics, Inc. COYA
$4.81 +1.69% Close, Oct 2, 2026 · NASDAQ · Market cap $112.8M
Strong growthExpensive vs sector
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $8.0M, up 1793.8% from a year earlier, accelerating from 115.4% a quarter earlier.
- Operating margin widened to -282.3% from -5342.3% a year earlier.
- The diluted share count rose 40.3% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 2%
- Revenue growth accelerationTop 1%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 32%
- Gross marginTop 4%
- Operating marginBottom 21%
- Accruals (lower is better)Bottom 3%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 30%
- Free-cash-flow yieldBottom 1%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 20%
- 6-month returnTop 39%
- 1-year return vs S&P 500Bottom 30%
- Distance from 52-week highBottom 43%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 26%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 47%
- Maximum drawdown, 3 yearsTop 39%
- Beta vs S&P 500 (lower is better)Bottom 37%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 115.4% | 1793.8% | ↑ |
| Gross margin | -2115.7% | 99.9% | ↑ |
| Operating margin | -5342.3% | -282.3% | ↑ |
| FCF margin | -3890.1% | -170613.5% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 1793.8% | 115.4% | ↑ | Top 2% |
| Gross margin | 99.9% | -2115.7% | ↑ | Top 4% |
| Operating margin | -282.3% | -5342.3% | ↑ | Bottom 21% |
| Net margin | -270.2% | -4803.1% | ↑ | — |
| Free-cash-flow margin | -170613.5% | -3890.1% | ↓ | — |
| Return on invested capital | -0.1% | — | Top 32% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 28.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 39176.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -9726.19%
- Shareholder yield
- -9726.19%
- Share count change, 1 year
- +40.3%
- Share count change, 3-year CAGR
- +33.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +0.3%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $12.00
- Target vs current price
- +149.5%
- Analysts with a rating
- 6
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | +19.0% | +3.4% | +0.6% | -0.6% | — |
| May 12, 2026 | +17.9% | +2.6% | +17.7% | +7.2% | +9.6% |
| Mar 16, 2026 | -24.8% | -0.7% | -7.1% | -1.8% | -1.1% |
| Nov 12, 2025 | -600.0% | +1.3% | +2.5% | +1.3% | -18.5% |
| Aug 12, 2025 | -63.6% | -0.3% | -2.3% | +2.0% | -4.9% |
| May 13, 2025 | +0.0% | -6.2% | -2.8% | -8.3% | -0.7% |
| Mar 18, 2025 | +30.8% | -5.8% | -2.9% | -20.4% | -17.8% |
| Nov 6, 2024 | +36.6% | +7.7% | +7.6% | -9.6% | -7.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.28 | -$0.35 | +19.0% | $221,873 |
| May 12, 2026 | -$0.32 | -$0.39 | +17.9% | $300,000 |
| Mar 16, 2026 | -$0.34 | -$0.27 | -24.8% | $4.0M |
| Nov 12, 2025 | -$0.10 | $0.02 | -600.0% | $3.6M |
| Aug 12, 2025 | -$0.36 | -$0.22 | -63.6% | $163,616 |
| May 13, 2025 | -$0.44 | -$0.44 | +0.0% | $257,884 |
| Mar 18, 2025 | -$0.18 | -$0.26 | +30.8% | $1,952 |
| Nov 6, 2024 | -$0.26 | -$0.41 | +36.6% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -12126.08% | — | — | Bottom 1% |
| Earnings yield | -22.25% | — | — | Bottom 30% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 12
- Days above the 200-day average
- 1
- 50-day average slope (20 days)
- -2.7%
- 200-day average slope (20 days)
- -2.6%
- Distance from 50-day average
- +2.7%
- Distance from 200-day average
- +1.5%
- RSI (14)
- 49.3
- Relative volume
- 0.59×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 54.2%
- Volatility vs own 5-year history
- 5th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.38
- Correlation with S&P 500
- 0.36
- Current drawdown from 1-year high
- -34.6%
- Maximum drawdown, 3 years
- -62.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 28, 2024 | Mar 30, 2026 | -62.9% | 354 days | Not yet recovered |
| Mar 15, 2024 | Aug 14, 2024 | -52.4% | 104 days | 52 days (Oct 28, 2024) |
| May 16, 2023 | Oct 4, 2023 | -43.4% | 97 days | 41 days (Dec 1, 2023) |
| Dec 28, 2023 | Jan 16, 2024 | -26.4% | 11 days | 21 days (Feb 14, 2024) |
| Jan 10, 2023 | Apr 5, 2023 | -22.6% | 59 days | 20 days (May 4, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $112.8M
- EPS, diluted (TTM)
- -$1.07
- Revenue (TTM)
- $8.0M
- 52-week range
- $3.71 – $7.75
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $6.0M | $3.6M | $7.9M |
| Gross profit | $0 | -$4.4M | $500,679 | -$8.3M | $7.9M |
| Operating income | -$4.9M | -$9.8M | -$7.9M | -$17.2M | -$20.3M |
| Net income | -$4.9M | -$12.2M | -$8.0M | -$14.9M | -$21.2M |
| EPS (diluted) | -$0.74 | -$1.23 | -$0.79 | -$0.98 | -$1.27 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1,952 | $257,884 | $163,616 | $3.6M | $4.0M | $251,147 | $243,745 |
| Net income | -$4.0M | -$2.9M | -$7.3M | -$6.1M | -$2.1M | -$5.7M | -$7.2M | -$6.6M |
| EPS (diluted) | -$0.26 | -$0.18 | -$0.44 | -$0.36 | -$0.13 | -$0.34 | -$0.32 | -$0.28 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$3.9M | -$7.2M | -$11.2M | -$10.3M | -$10.7M |
| Capital expenditure | -$136,804 | $0 | $0 | $0 | $0 |
| Free cash flow | -$4.0M | -$7.2M | -$11.2M | -$10.3M | -$10.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $1,317 | $158 | $38.3M | $14.0M | $20.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $43.18B
- Total assets
- $47.31B
- Total liabilities
- $4.03B
- Total debt
- $0
- Net debt
- -$43.18B
- Shareholders’ equity
- $43.28B
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 1,187,873
- Days to cover
- 10.24
- Change vs previous report
- +9.4%
FINRA short interest, settlement date Sep 15, 2026.